QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.105.086504v1 314/2/626    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leeder, J. S. Articles by Pearce, R. E. Search for Related Content PubMed PubMed Citation Articles by Leeder, J. S. Articles by Pearce, R. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB TESTOSTERONE

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Variability of CYP3A7 Expression in Human Fetal Liver

Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Department of Pediatrics, Children's Mercy Hospital and Clinics, Kansas City, Missouri

Received for publication March 17, 2005
Accepted April 18, 2005.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Fetal liver CYP3A7 plays an important role in placental estriol synthesis during pregnancy, yet little is known concerning the extent or consequences of variability in expression. The purpose of this investigation was to characterize the variability in CYP3A7 expression using several phenotypic measures in a panel of 54 fetal livers ranging in age from 76 days to 32 weeks gestation. CYP3A7 mRNA expression was measured using quantitative polymerase chain reaction, whereas immunoreactive CYP3A7 was determined using an affinity-purified antipeptide antibody. Variability in catalytic activity was evaluated using testosterone and dehydroepiandrosterone (DHEA) as substrates. Across the entire panel, CYP3A7 was the most abundant CYP3A mRNA species present and varied 634-fold from 151 to 95,700 transcripts/ng total RNA, corrected for 18S ribosomal RNA. CYP3A4 expression was minimal based on mRNA expression (1000-fold lower than CYP3A7) and the ratio of testosterone 2- (T2H) to 6- (T6H) hydroxylation. T2H and T6H were highly correlated (r² = 0.859), and the correlation increased (r² = 0.974) in livers with CYP3A5*3/*3 genotypes implying that the same enzyme (CYP3A7) generated both products. Overall, T2H and DHEA16H activities varied 175- and 250-fold, respectively. A subset of five samples had extremely low mRNA, protein, and catalytic activity, possibly due to pathology affecting fetal viability (anencephaly, porencephaly). In the remaining samples, T2H activity varied 6.7-fold (358 ± 142, range 97 to 643 pmol/min/mg) and DHEA16H activity varied 6.2-fold (8.07 ± 2.87, range 2.41 to 14.9 nmol/min/mg). Observed variability in CYP3A7 activity was not related to CYP3A7*2, and alternative regulatory mechanisms require further investigation.

For over 40 years, estriol has been recognized as the "pregnancy estrogen". It is an important determinant of fetal growth and development as well as timing of parturition (Mesiano and Jaffe, 1997), and its biosynthetic pathway exemplifies a network of effector ligand-metabolizing enzymes. For example, SULT2A1 is responsible for dehydroepiandrosterone 3-sulfate (DHEA-S) synthesis in the fetal adrenal, and the majority of DHEA-S subsequently undergoes 16-hydroxylation in the fetal liver (and, to a lesser extent, within the adrenal itself) (Serón-Ferré and Jaffe, 1981), an activity that has been attributed to CYP3A7 (Kitada et al., 1987). After uptake into placental syncytiotrophoblasts, DHEA-S and 16-hydroxydehydroepiandrosterone 3-sulfate (16DHEA-S) are deconjugated by sulfatase to generate dehydroepiandrosterone (DHEA) and 16-hydroxydehydroepiandrosterone (16DHEA), the primary C₁₉ steroid precursors for aromatase (CYP19)-mediated estradiol and estriol synthesis, respectively (Ryan, 1959; Baulieu and Dray, 1963; Siiteri and MacDonald, 1963).

CYP3A7 would appear to have important functions in addition to its role in estriol biosynthesis. Catalytic activity attributed to CYP3A7 has been observed in embryonic liver as early as 50 to 60 days gestation (Yang et al., 1994). Expression has been reported to increase throughout pregnancy, peaking at 2 weeks postnatal age, and declining thereafter to the low levels characteristic of adult liver (Lacroix et al., 1997), although more recent data suggest that activity declines throughout the last trimester of pregnancy (Stevens et al., 2003). Nevertheless, DHEA-S in high concentrations is associated with inhibition of cell proliferation and progesterone synthesis, leading to speculation that functional DHEA-S 16-hydroxylation may also play a fetoprotective function (Schuetz et al., 1993). Consistent with this hypothesis, DHEA-S and other 3-S-conjugated steroids have been reported to activate the catalytic activity of CYP3A7, but not CYP3A4 (Nakamura et al., 2003). Furthermore, given its catalytic activity toward the 4-hydroxylation of 9-cis and all-trans-retinoic acid (Chen et al., 2000; Marill et al., 2000, 2002), CYP3A7 may also provide protection against the embryotoxic effects of retinoic acid, particularly from exogenous exposure following maternal ingestion of therapeutic doses. Finally, it appears that CYP3A7 also possesses the capacity to bioactivate several promutagens, including aflatoxin B₁ (Li et al., 1997).

Given these considerations and the fact that the extent of interindividual variation in fetal liver CYP3A7 activity is essentially unknown, the purpose of this investigation was to characterize the extent of variability in CYP3A7 mRNA transcripts, protein expression, and catalytic activity toward endogenous and xenobiotic substrates in a panel of fetal liver tissues. Since the DHEA 16-hydroxylation activities reported by Stevens et al. (2003) were approximately 10-fold higher than those reported by Lacroix et al. (1997), estimates of catalytic activity and expression levels of mRNA are critically dependent upon tissue quality. Furthermore, difficulty in discriminating between CYP3A4 and CYP3A7 activities and immunoreactive protein content has been a historical problem when using conventional probes of CYP3A activity and commercially available antibodies (Stevens et al., 2003). To address these issues, the current investigation implemented strict tissue selection criteria and utilized a variety of experimental approaches to unambiguously differentiate CYP3A7-related activity from that of CYP3A4 or CYP3A5.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Materials and Reagents. Testosterone, androstenedione, 2-hydroxytestosterone, 2-hydroxytestosterone, 6-hydroxytestosterone, 15-hydroxytestosterone, glucose-6-phospate, glucose-6-phosphate dehydrogenase, NADP, and EDTA were purchased from Sigma-Aldrich (St. Louis, MO). DHEA and 16DHEA were purchased from Steraloids (Newport, RI). All other reagents were of analytical grade. Microsomes prepared from baculovirus-infected insect cells (SUPERSOMES) expressing human P450 enzymes CYP1A1, -1A2, -1B1, -2A6, -2B6, -2C8, -2C9, -2C18, -2C19, -2D6, -2E1, -3A4, -3A5, -3A7, or control vector were purchased from BD Gentest (Woburn, MA). Criterion 4 to 15% Tris-HCl gels and Tris/glycine/SDS running buffer were purchased from Bio-Rad (Hercules, CA). Hybond C-Super nitrocellulose, ECL anti-rabbit IgG horseradish peroxidase-conjugated antibody, ECL Plus Detection Kit, and Hyperfilm were purchased from Amersham Biosciences Inc. (Piscataway, NJ).

Liver Samples. A total of 54 liver samples 76 days to 32 weeks estimated gestational age (EGA) were obtained through the National Institute of Child Health and Human Development-supported tissue retrieval programs, 26 from the Central Laboratory for Human Embryology at the University of Washington (Seattle, WA), and 28 from the Brain and Tissue Bank for Developmental Disorders at the University of Maryland (Baltimore, MD). Available demographic data are presented in Table 1. Tissues were stored at –70°C prior to preparation of subcellular fractions. The post-mortem interval was 2 h or less for 49 samples; five had post-mortem intervals of 3 h (n = 2), 4 h (n = 1), 5 h (n = 1), and 6 h (n = 1). The use of these tissues was approved by the University of Missouri-Kansas City Pediatric Health Sciences Review Board.

Preparation of Fetal Liver Microsomes. Microsomes were prepared from 51 of the 54 human fetal livers by differential centrifugation according to the method of Lu and Levin (1972). Isolated microsomal pellets were removed from centrifuge tubes with a Teflon-coated spatula, transferred to a low-volume glass mortar (tapered, 4 ml), manually resuspended in 0.25 M sucrose with a tapered Teflon pestle, and stored at –70°C until use. Protein concentrations were determined using the Micro BCA Protein Assay kit (Pierce Chemical Co., Rockford, IL).

RNA Extraction and Quantitative Reverse Transcriptase (QRT)-PCR Analysis. Frozen liver tissues (20 to 30 mg) were homogenized and total RNA extracted according to the QIAGEN RNeasy protocol (QIAGEN, Valencia, CA) with an on-column DNase I treatment. The quality of the isolated RNA was assessed by agarose gel electrophoresis, and RNA quantity was determined spectrophotometrically. For one-step QRT-PCR reactions, RNA was diluted to 5 ng/µl, and 25 ng were used in a reaction volume of 20 µl. Primer pairs designed to specifically bind in exon 1 and exon 4 of each of the four CYP3A isoforms (Table 2) were used at a final concentration of 250 nM. Reactions were performed in triplicate with the QuantiTect SYBR Green one-step RT-PCR kit (QIAGEN) on a DNA Engine Opticon 2 instrument (MJ Research, Watertown, MA). Serial dilutions of PCR amplicons for each of the four specific CYP3A isoforms were used to generate standard curves ranging from 100 to 10⁷ copies. CYP3A mRNA transcript numbers were calculated from linear regression analysis of the respective standard curves. Data were normalized to 18S rRNA using the TaqMan Ribosomal RNA Control Reagent kit (Applied Biosystems, Foster City, CA).

Specificity of the assays for the four CYP3A isoforms was confirmed by sequencing the amplicons and further determined by comparative QRT-PCR experiments, wherein each CYP3A isoform-specific primer set was tested for specificity against 10⁶ molecules of CYP3A4, CYP3A5, CYP3A7, and CYP3A43 templates. When the CYP3A7 primer set was used under the experimental conditions described above, a cycle threshold (Ct) difference of >14 cycles was observed between the CYP3A7 template and the other three templates (i.e., Ct values were >14 cycles greater for CYP3A4, CYP3A5, and CYP3A43 than that observed with the CYP3A7 template). Using the CYP3A4, CYP3A5, and CYP3A43 primer sets, differences in Ct values were greater than 13 cycles between the cognate and alternative targets.

Preparation of Anti-CYP3A7/4 Antibody. The primary antibody was raised in rabbits against the C-terminal pentapeptide of CYP3A4 and -3A7, Thr-Val-Ser-Gly-Ala, that had been conjugated to keyhole limpet hemocyanin using sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate chemistry via a cysteine residue added to the N terminus of the pentapeptide. Pathogen-free New Zealand White rabbits (HsdOkd:NZW) were immunized with 1 mg of peptide-keyhole limpet hemocyanin antigen emulsified in Freund's Complete Adjuvant followed by secondary immunizations on days 28, 56, and 84. Production bleeds (25 ml) were obtained on day 98 and day 105 followed by complete exsanguination on day 112. Antigen preparation and antibody production was carried out by Harlan (Indianapolis, IN).

To minimize nonspecific binding, the antipeptide antibody was affinity purified using the PinPoint Xa Protein Purification System (Promega, Madison, WI). Oligonucleotides (sense, 5'-AGCTTTGCACCGTGAGCGGCGCGTAAG-3' and antisense, 5'-GATCCTTACGCGCCGCTCACGGTGCAA-3') encoding the CYP3A4/7 pentapeptide were synthesized (Sigma-Genosys, The Woodlands, TX), allowed to anneal, phosphorylated with T4 polynucleotide kinase, and ligated into the PinPoint Xa-3 vector between the HindIII and BamHI restriction sites to create an in-frame fusion with the biotinylated target sequence encoded by the vector. Clones were sequenced to confirm the presence of the oligonucleotide insert. The pentapeptide epitope was expressed in Escherichia coli as the C terminus of a biotinylated fusion protein. An affinity column was prepared by immobilization of the biotinylated fusion protein on TetraLink Tetrameric Avidin Resin (Promega). Antipeptide antibodies were allowed to bind to the fusion protein solid phase, the column washed with >5 bed volumes of buffer, and bound antibodies eluted with 100 mM glycine, pH 2.8. The antibody was specific for CYP3A4 and -3A7 and did not react with heterologously expressed CYP1A1, -1A2, -2A6, -2B6, -2C8, -2C9, -2C19, -2D6, -2E1, or -3A5.

Immunoquantitation of Microsomal CYP3A7/4 Protein. Fetal liver microsomes were diluted in sample buffer (10% glycerol, 141 mM Tris base, 106 mM Tris-HCl, 2% SDS, 0.51 mM EDTA, 0.22 mM SERVA Blue G250, and 0.175 mM Phenol Red) containing fresh 50 mM dithiothreitol and heated for 10 min at 70°C. Microsomal proteins, 0.5 µg per lane, were separated on 4 to 15% Criterion 26-well gels in running buffer (25 mM Tris, 192 mM glycine, and 0.1% w/v SDS, pH 8.3) at 200 V for 45 min. Proteins were transferred to nitrocellulose membranes using a Bio-Rad Semi-dry transfer unit with transfer buffer containing 39 mM glycine, 48 mM Tris, 0.0375% SDS, and 20% methanol. Membranes were blocked overnight at room temperature on a rocker in 10 mM Tris, 150 mM NaCl, 0.2% Tween 20, pH 8.0 (TNT) containing 4% skim milk powder (M-TNT). Blocked membranes were incubated for 1 h with affinity-purified anti-CYP3A7/4 antibody diluted 1:20,000-fold in M-TNT and washed with TNT (5 min x 6). To detect bound antibody, blots were incubated with horseradish peroxidase-conjugated donkey anti-rabbit antibody (1:50,000) in M-TNT for 30 min, washed (5 min x 6), incubated with ECL Plus chemiluminescence reagents according to the manufacturer's directions (Amersham Biosciences Inc.), and exposed on Hyperfilm ECL. Films were scanned using a flat-bed scanner, and densitometric analysis of immunoreactive protein was conducted using Kodak Digital Science 1D Image Analysis Software, version 3.6 (Eastman Kodak Company, Rochester, NY). Standard curves (0.025 to 0.3 pmol per lane heterologously expressed CYP3A7; BD Gentest) were present on each membrane. Standard curves were linear over the range of standards, and coefficients of determination (r² values) ranged from 0.972 to 0.999. Back-extrapolated values for the standards were within 3.6 to 8.8% of the nominal values between 0.3 and 0.05 pmol, and within 29.9% of the nominal value for the 0.025 pmol standard. Values presented are the mean of duplicate determinations.

Incubation Conditions for Catalytic Activity Assays. In vitro enzyme assays were performed in 96-well microtiter plates. Standard incubation reactions (100 µl) contained microsomes prepared from fetal human liver (5–50 µg of microsomal protein) or insect cell microsomes containing baculovirus-expressed cytochrome P450 enzymes (1–5 pmol) coexpressed with P450 reductase, potassium phosphate buffer (50 mM, pH 7.4), MgCl₂ (3 mM), EDTA (1 mM), and substrate (250 µM testosterone; 100 µM DHEA). Reactions were initiated by the addition of an NADPH-generating system consisting of NADP (1 mM), glucose 6-phosphate (1 U/ml), and glucose-6-phosphate dehydrogenase (5 mM), placed in a Thermo Forma (Marietta, OH) Benchtop Orbital Shaker incubator at 37 ± 0.1°C, and terminated after 10 to 30 min by the addition of 100 µl of ice-cold methanol. Protein was precipitated by centrifugation at 10,000g_max for 10 min. An aliquot (20–100 µl) of the supernatant was analyzed by reversed-phase HPLC via direct injection. Under these conditions, metabolism of the parent compounds did not exceed 20%, and rates of metabolite formation were proportional to incubation time and protein concentration. Duplicate determinations were performed for each sample.

Analytical Methods. HPLC analyses were performed with a Hewlett Packard HP1100 HPLC system with programmable 1100 series diode array and fluorescence detectors (Hewlett Packard Instruments, Santa Clara, CA). All data were collected and integrated with Hewlett Packard Chemstation V A.0401 software. Testosterone and its 2-, 2-, and 6-hydroxylated metabolites were resolved by reversed-phase HPLC via direct injection according to the method of Purdon and Lehman-McKeeman (1997), as modified by Usmani et al. (2003). Under these conditions, 6-, 15-, 6-, 2-, and 2-hydroxytestosterone, androstenedione, and testosterone had retention times of 14.8, 15.9, 16.4, 20.8, 21.6, 25.0, and 28.0 min, respectively. The solvent program was modified slightly such that 16DHEA eluted at 17.0 min and DHEA eluted at 27.2 min. The analytical methods demonstrated linearity (r² = 0.999) over the range of standards evaluated (5 to 1250 pmol of testosterone metabolites and 5 to 1500 pmol of 16DHEA injected).

Genomic DNA Isolation and Genotyping for CYP3A7*1B, -*1C, and -*1E Allelic Variants. Genomic DNA was isolated from 5 to 25 mg of tissue using a DNeasy Tissue Kit (QIAGEN). CYP3A7*1C genotyping was adapted from Burk et al. (2002) with the following modifications: a 2468-bp long fragment was amplified from genomic DNA in a 15-µl reaction using JumpStart REDTaq DNA polymerase (Sigma-Aldrich), the buffer provided with the enzyme, and 0.2 µM each primer (listed in Table 2). After PCR amplification, 12 µl of a mixture containing 2.5 units of SspI and NEB digestion buffer "U" (New England Biolabs, Beverly, MA) was added to each reaction and incubated overnight at 37°C. Restriction fragments were separated on an agarose gel by electrophoresis and documented with a Kodak 440 CF Image Station (Eastman Kodak Co., New Haven, CT). A CYP3A7*1/*1C sample was included as a positive control.

To confirm the CYP3A7*1C genotype and to genotype for CYP3A7*1B, -*1D, and -*1E alleles, genomic DNA was amplified with JumpStart REDTaq DNA polymerase (Sigma-Aldrich) and 0.2 µM oligonucleotide primers 3A7 197291-F (5'-CACCTCTGCTAAGGGAAACAGGCC) and 3A7 198150-R (5'-GCCAGCCTGAACATCCTTTTTGCTA). Specificity of both PCR primers was achieved by aligning the four CYP3A genes and the two pseudogene sequences CYP3AP1 and CYP3P2 using the LAGAN algorithm (Brudno et al., 2003). The 859-bp amplicon encompassing 680 bp of the proximal promoter, exon 1 and 109 bp of intron 1 was treated with ExoSAP-IT [USB (U.S. Biochemical Corp.), Cleveland, OH] and subsequently sequenced with the DY-Enamic ET Dye Terminator Cycle Sequencing Kit for MegaBACE (Amersham Biosciences Inc.). Unincorporated fluorescent dye-terminators were removed from the reactions by solid-phase magnetic CleanSEQ beads (Agencourt, Beverly, MA) according to the manufacturer's recommendations prior to analysis on a MegaBACE 500 DNA Analysis System. The data were analyzed with the Phred/Phrap/Consed software package (University of Washington, Seattle, WA).

Genotyping for CYP3A7*2 by Extra-Long-PCR Sequencing. To detect the g.26041C>G (Thr409Arg) variant, a CYP3A7-specific 6.51-kb long PCR amplicon including exons 11 to 13 was generated with Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA) and primers 3A7 223378-F (5'-CAATAATCCTTGTCGCACAGAGAATTTG) and 3A7 229891-R (5'-ATAATTTGGAGTTATCATTTGGAGGGTCT). Reaction conditions were as follows: denaturing, 94°C for 20 s; annealing, 64°C for 30 s; and extension, 68°C for 6 min, for 40 cycles. The GenBank entry NG_000004 [GenBank] .2 was used to design the amplification primers. The PCR reaction was subsequently cleaned up as described above, and a 0.8-µl aliquot was sequenced with primers 3A7 223735-F (5'-TCAACAGTACTACATGGACTG) and 3A7 224241-R (5'-GGGACTGTGACTGGCTATAG).

Genotyping CYP3A5 Allelic Variants. PCR-RFLP-based assays for CYP3A5*3, CYP3A5*4, and CYP3A5*5 were adapted from published methods (van Schaik et al., 2002) or developed de novo (CYP3A5*2, CYP3A5*6, and CYP3A5*7). Complete assay details are presented in Table 3. Assays for CYP3A5*2, CYP3A5*3, and CYP3A5*7 were conducted using genomic DNA with 40 cycles of amplification. Improved assay performance for the CYP3A5*4, CYP3A5*5, and CYP3A5*6 alleles was achieved using an 8152-bp long CYP3A5-specific template generated with Platinum Taq DNA Polymerase High Fidelity according to the manufacturer's recommendations (Invitrogen) with 10-s annealing at 70°C and 9-min extension at 68°C for 35 cycles (primers listed in Table 3). All other PCR reactions were conducted with JumpStart REDTaq DNA polymerase (Sigma-Aldrich) using the buffer provided with the enzyme except for the CYP3A5*7 product, which was generated using Fail-Safe buffer C (Epicenter Technologies, Madison, WI). After PCR amplification, an equal volume (8 µl) containing the relevant restriction enzyme (New England Biolabs and Amersham Biosciences Inc.) and digestion buffer was added to each reaction and incubated for at least 2 h. PCR-RFLP fragments were separated by gel electrophoresis (3% agarose gels containing Synergel; Diversified Biotech, Boston, MA) and documented as described above.

Statistical Analysis. Results are reported as the mean ± S.D. Measures of linkage disequilibrium were determined using Haploview version 3.11 (Barrett et al., 2005). Univariate linear regression and ANOVA with Tukey's post hoc analysis were conducted using SPSS version 12 for Windows (SPSS Inc., Chicago, IL). p < 0.05 was accepted as a statistically significant difference.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Variability in CYP3A Gene Transcription in Human Fetal Liver. Expression of CYP3A mRNAs is reported as transcripts per nanogram total RNA corrected for the expression of 18S rRNA as recommended by Koch et al. (2002). Although RNA quality demonstrated some variability across the panel of specimens, prominent 18S and 28S bands were evident in all samples (not shown), and values for 18S rRNA expression varied only 3.9-fold in this sample set (mean ± S.D., 4.97 ± 1.55 x 10⁷ transcripts/ng total RNA; range, 2.48 x 10⁷ to 9.73 x 10⁷ transcripts/ng total RNA).

View larger version (19K): [in this window] [in a new window]   Fig. 1. Comparative expression of CYP3A7 (solid inverted triangles), CYP3A5 (open circles), CYP3A4 (solid circles), and CYP3A43 mRNA (open inverted triangles) in human fetal liver relative to EGA. Data are expressed as transcripts per nanograms per total RNA and are normalized for 18S ribosomal RNA content.

Variability in CYP3A7/4 Immunoreactive Protein. Immunoreactive CYP3A7/4 protein content was determined for 51 of the 54 fetal liver samples and averaged 234.8 ± 123.1 pmol CYP3A7/4 protein/mg microsomal protein (Table 4). A representative immunoblot (standard curve: r² = 0.972) illustrating a range of immunoreactive protein contents is presented in Fig. 2A. CYP3A7 remained undetectable in one sample (CMM1153) even when the amount of protein loaded was increased 4-fold to 2 µg/lane. For samples with detectable protein, CYP3A7/4 content varied 21.6-fold from 20.6 to 439.9 pmol/mg microsomal protein. Although samples with the lowest CYP3A7 mRNA expression also had the lowest immunoreactive CYP3A7/4 protein expression, the overall correlation was poor (r² = 0.129). Likewise, immunoreactive CYP3A7/4 protein across all samples was poorly correlated with EGA (r² = 0.149; Fig. 2B). Significant correlations were, however, observed between protein content and both testosterone 2-hydroxylation (T2H; r² = 0.541, p < 0.01; Fig. 2C) and DHEA 16-hydroxylation (DHEA16H; r² = 0.585, p < 0.01; Fig. 2D) activities.

View larger version (31K): [in this window] [in a new window]   Fig. 2. CYP3A7/4 immunoreactive protein in fetal liver. Immunoreactive CYP3A7/4 protein content was determined using an affinity purified anti-C-terminal peptide antibody that did not differentiate between CYP3A7 and CYP3A4. A, representative immunoblot containing a five-point standard curve from 0.025 to 0.3 pmol heterologously expressed CYP3A7 (BD Gentest) per lane. B, immunoreactive protein content as a function of estimated gestational age (r2 = 0.149). C, correlation between testosterone 2-hydroxylation activity and immunoreactive protein content (r2 = 0.541; p < 0.01). D, correlation between DHEA 16-hydroxylation activity and immunoreactive protein content (r2 = 0.585; p < 0.01).

Testosterone Biotransformation. Since published data indicated that human CYP3A isoforms demonstrated regiospecific patterns of testosterone biotransformation (Usmani et al., 2003), we investigated the potential for testosterone 6-hydroxylation (T6H) and T2H activities to determine the relative contributions of CYP3A isoforms toward catalytic activities in human fetal liver. Product formation using heterologously expressed rCYP3A4, rCYP3A5, and rCYP3A7 (and experimental conditions identical for those to be employed for incubations containing fetal liver microsomal protein) are presented in Table 5. The ratio of T2H and T6H activities (T2H/T6H ratio) appeared to be particularly useful for discriminating among the three CYP3A isoforms since the rCYP3A7 value of 1.19 was an order of magnitude greater than the rCYP3A5 value of 0.079, which was approximately 10-fold greater than the ratio of 0.007 determined with rCYP3A4 (Table 5).

In the fetal liver microsomal samples, the T2H/T6H ratio was 1.71 ± 0.32 with a minimum value of 0.54 and a maximum value of 2.14 (Fig. 3). The value of 1.19 associated with rCYP3A7 was exceeded in 49 of 51 samples, the exceptions being samples with values of 0.54 and 1.17, respectively. The lowest ratio, 0.54, was observed in a sample with very low T2H and T6H activities of 6.4 and 11.9 pmol/min/mg protein, respectively. To address potential contributions from CYP3A5, the samples were genotyped for the CYP3A5 intron 3 polymorphism (g.6986A>G). ANOVA revealed a statistically significant inverse relationship between the T2H/T6H ratio and the number of functional g.6986A alleles (reference sequence as defined by the Human Cytochrome P450 Nomenclature Committee; http://www.imm.ki.se/CYPalleles/cyp3a5.htm; F = 7.01, p = 0.002; not shown). The presence of functional CYP3A5 protein has been confirmed in these samples by immunoblot analysis and midazolam hydroxylation (data not shown; manuscript in preparation). Although considerable overlap among groups was observed, post hoc analysis with Tukey's honestly significant difference confirmed that at least one g.6986A allele resulted in significantly lower ratio values compared with two g.6986G alleles. It should be noted that both CYP3A5*1 and -*6 alleles genotype as g.6986A, although the CYP3A5*6 allele is associated with reduced activity due to an additional downstream splicing defect (Rogan et al., 2003). For the sample with the lowest T2H/T6H ratio, the contribution of CYP3A5 likely is minimal since this sample was genotyped as CYP3A5*3/*6, and neither immunoreactive CYP3A5 protein nor midazolam hydroxylation activity was detected (not shown).

View larger version (17K): [in this window] [in a new window]   Fig. 3. Distribution of the ratio between testosterone 2-hydroxylase and testosterone 6-hydroxylase activities in the panel of human fetal liver microsomes. The frequency distribution of observed T2H/T6H ratios is overlaid with a Q-Q plot of the same data.

View larger version (21K): [in this window] [in a new window]   Fig. 4. Correlation between T2H activity and T6H activity (A) and between T2H activity and DHEA16H activity (B). Samples were genotyped for the CYP3A5 g.6986A allele. Samples having at least one CYP3A5 g.6986A allele are indicated with solid circles, whereas those with two CYP3A5 g.6986G alleles (assigned a CYP3A5*3/*3 genotype) are presented as open circles. Samples where the sole "functional" allele is CYP3A5*6 (CYP3A5*3/*6 genotypes) are presented as solid circles with a white diagonal line. The sample genotyped as CYP3A5*6/*6 is indicated by the solid circle with perpendicular diagonal lines.

DHEA16H Activity. Fetal liver microsomes were more active toward DHEA as a substrate than toward testosterone. Mean ± S.D. DHEA16H activity was 7.30 ± 3.61 nmol product formed/min/mg microsomal protein. Values varied approximately 250-fold ranging from 0.059 to 14.91 nmol/min/mg when all samples were included in the analysis but varied only 6.2-fold when the low activity samples were excluded. DHEA16H activity was significantly correlated with T2H activity (r² = 0.856, p < 0.0001) but was not affected by CYP3A5 genotype (Fig. 4B). A weak (r² = 0.256) but statistically significant (F = 15.96, p = 0.0002) correlation was observed between DHEA16H activity and EGA, but as observed for T2H activity, this relationship was dependent upon the presence of the set of samples with extremely low activity (not shown). There was no relationship between DHEA16H activity and the total length of time that the tissues were stored prior to isolation of microsomes (r² = 0.002).

Association of CYP3A7 Allelic Variants with Measures of CYP3A7 Expression. Since DHEA16H activity did not appear to be influenced by CYP3A5 genotype, subsequent phenotype-genotype correlations were evaluated using this measure. No CYP3A7*1B, -*1C, or -*1D alleles were observed in this sample set, whereas three African-American and one Caucasian sample were heterozygous for the CYP3A7*1E allele (F = 0.037). No relationship between CYP3A7*1E and DHEA16H activity was apparent (values of 0.09, 4.4, 9.0, and 12.4 nmol/min/mg).

The frequency of the CYP3A7*2 allele in this set of fetal samples was 0.378 and was in linkage disequilibrium with CYP3A5*3 (D' = 0.90 with 95% confidence interval 0.76 to 0.93; r² = 0.74). No association was observed between DHEA16H activity and the number of CYP3A7*2 alleles by ANOVA (F = 0.326, p = 0.724; Fig. 5).

View larger version (13K): [in this window] [in a new window]   Fig. 5. Relationship between DHEA16H activity and CYP3A7 genotype. Presence of the CYP3A7*2 allele was determined by direct sequencing as described under Materials and Methods. The subset of samples with extremely low immunoreactive protein and catalytic activity was excluded from the analysis to minimize potential confounding effects such as disease pathology and tissue quality.

	Discussion

Top Abstract Materials and Methods Results Discussion References

Although 170- to 250-fold variability in testosterone and DHEA hydroxylation and 634-fold variability in CYP3A7 mRNA expression was observed across the entire panel, most of this variability could be attributed to the presence of a subset (n = 5) of samples with extremely low values. Variability in catalytic activity was 10-fold or less for the remaining samples (Table 4). It is unlikely that poor sample quality was a major factor contributing to the observed interindividual variability for several reasons. The post-mortem interval was2hor less for 49 of the 54 samples. Furthermore, 18S rRNA values demonstrated minimal (3.9-fold) variation, consistent with the observations of Koch et al. (2002) in adult liver, and no correlation was observed between either the post-mortem interval or 18S rRNA value and any measure of CYP3A7 expression.

A major concern in characterizing the extent of variability in CYP3A7 activity has been ascertaining the contribution of even minimal amounts of CYP3A4 (or CYP3A5) present in a sample due to the overlapping activities toward probe substrates by these closely related CYP3A isoforms and the lack of specificity of antibody reagents used for immunoquantitation (Stevens et al., 2003). In the set of fetal liver samples investigated for this report, expression of CYP3A4 appeared to be minimal based on relative mRNA expression and catalytic activity toward testosterone. The average T6H activity in this panel of fetal liver microsomes was 186.6 pmol/min/mg protein with a maximum value of 439.4 pmol/min/mg, markedly lower than activities of approximately 800 to 14,000 pmol/min/mg reported in adult liver microsomes (Pearce et al., 1996). Observed regiospecific patterns of testosterone hydroxylation also were more consistent with a pattern of catalysis dominated by CYP3A7 activity rather than by CYP3A4 activity (Usmani et al., 2003). For example, T2H activity measured in fetal liver microsomes exceeded T6H activity in all samples but one, and in 49 of 51 samples, the observed T2H/T6H ratio was greater than the value of 1.186 established with rCYP3A7. Moreover, the lowest observed ratio in fetal liver microsomes (0.535) was considerably greater than the values of 0.079 and 0.007 observed with rCYP3A5 and rCYP3A4, respectively. Finally, visual inspection of HPLC chromatograms from analyses of DHEA biotransformation failed to reveal any peaks that would correspond to 7-hydroxyDHEA formation by fetal liver microsomes, a product that is highly specific to CYP3A4 (Stevens et al., 2003).

In contrast, CYP3A5 may be more likely to confound estimates of CYP3A7 expression since CYP3A5 immunoreactive protein has been detected in approximately 50% of fetal liver microsomal samples (Hakkola et al., 2001; Stevens et al., 2003). In our panel, genotyping for CYP3A5 g.6986A>G identified a subset of samples where the expression of CYP3A5 protein was predicted to be negligible (CYP3A5*3/*3). The high correlation between T2H and T6H activities (r² = 0.974) for CYP3A5*3 homozygotes strongly suggests that a single enzyme, CYP3A7, was primarily responsible for both activities. In contrast, DHEA16H activity was not affected by CYP3A5 genotype providing support that it is a more specific marker of CYP3A7 activity than testosterone in fetal liver microsomes, i.e., under conditions where CYP3A4 expression is minimal or absent. The fact that CYP3A5 genotyping segregates testosterone hydroxylation activity, but not DHEA16H activity, into two groups suggests that CYP3A5 may contribute to the biotransformation of some substrates but not others in fetal liver. A more detailed characterization of CYP3A5 activity in this panel is currently in preparation.

Our estimate of average CYP3A7 content in fetal liver microsomes is in agreement with one published report (Stevens et al., 2003) but higher than that reported by others (Lacroix et al., 1997). Stevens et al. exploited differential patterns of DHEA 16- and 7-hydroxylation by CYP3A7 and CYP3A4 in conjunction with a validated nonlinear multivariate regression model to calculate CYP3A4 and CYP3A7 protein in a subset of pre- and postnatal livers. Using this innovative but indirect measure, they observed an average CYP3A7 content of 311 pmol/mg microsomal protein in the second trimester, 201 pmol/mg in the third trimester, and 158 pmol/mg in premature birth samples, suggesting that increasing gestational age may also contribute to the observed variability in CYP3A7 expression (Stevens et al., 2003). Published data are conflicting in this regard (Lacroix et al., 1997), and only a weak association between EGA and CYP3A7 activity was observed across the entire panel of samples in our investigation due, most likely, to the limited number of late term samples. Nevertheless, it is likely that factors other than EGA are responsible for the extremely low values of CYP3A7 activity observed in our study since Stevens et al. (2003) reported only a 50% decrease in CYP3A7 content between second trimester samples and samples from prematurely born infants.

Since CYP3A5 genotype did not have any discernable effect on DHEA16H activity, this measure was considered to best reflect variability in CYP3A7 expression. We speculate that the extreme range observed in the current study does not reflect normal variability in fetal liver CYP3A7 activity since variability was only 6.2-fold when the subset of low samples was excluded. Furthermore, three of the samples in the "low activity" group were obtained from fetuses with severe congenital anomalies—anencephaly, porencephaly, and hydrops fetalis. Although hepatic dysfunction generally is not considered to be associated with either anencephaly or porencephaly, hypothalamic-pituitary function is disrupted in anencephalic fetuses such that adrenocorticotropin levels are insufficient to support fetal adrenal development as inferred from dramatically reduced maternal estrogen concentrations (Mesiano and Jaffe, 1997). Although regulation of estrogen biosynthesis is severely dysregulated under these conditions, the effects on CYP3A7 activity are less clear. Milewich et al. (1986) observed that 16-hydroxylase activity toward estrone sulfate and estradiol sulfate was similar in anencephalic fetuses (gestational ages not reported) compared with normal fetuses, although activities were markedly lower in one of a pair of twin anencephalic fetuses. However, the relative paucity of available information makes it impossible to know whether the extremely low CYP3A7 activity was due to fetal pathology or poor tissue quality (subject to the considerations discussed above). The 6- to 7-fold variation in activity observed in the majority of samples more likely represents true variability within the viable fetal population.

Persistence of CYP3A7 mRNA expression postnatally has been associated with the presence of the CYP3A7*1C allele (Kuehl et al., 2001). No CYP3A7*1C alleles were observed among our 54 fetal samples, although we have observed an allele frequency of 2.3% in an African-American control population (n = 87). Thus, the CYP3A7*1C allele does not contribute to the observed variability in mRNA expression or catalytic activity observed in fetal liver. Genotyping for the previously described CYP3A7*2 allele (Rodriguez-Antona et al., 2005) also could not account for the variation observed in any of the in vitro phenotypic measures investigated. Although Rodriguez-Antona et al. (2005) reported moderately higher DHEA hydroxylation for the CYP3A7*2 allele, the tendency of this allele to demonstrate higher DHEA16H activity among our fetal panel did not achieve statistical significance. However, genotype-phenotype correlations may be obscured by the fact that CYP3A7 activity has been reported to be activated by steroid sulfate conjugates, such as pregnenolone 3-sulfate, 17-hydroxypregnenolone 3-sulfate, and DHEA-S, but not the corresponding unconjugated forms (Nakamura et al., 2003). Thus, activity/phenotype of the wild-type and variant proteins may be differentially affected by the specific substrate concentration used in the in vitro analyses.

The overall variability in CYP3A7 activity observed in this study may seem inconsistent with an important physiological function, but exclusion of a low activity subgroup resulted in only 6- to 7-fold variability in catalytic activity. Comparative analyses revealed that in vitro clearance of prototypic CYP3A substrates is generally 5- to 10-fold lower for CYP3A7 compared with CYP3A4 (Williams et al., 2002), implying a primarily physiological role for CYP3A7 in fetal liver. Given the importance of CYP3A7 to estriol biosynthesis during pregnancy and its potential to provide protection against exogenous sources of retinoic acid esters, a thorough understanding of allelic variation, alternative splicing, and developmental expression of trans-acting factors potentially involved in regulating CYP3A7 expression, such as pregnane X receptor, constitutive androstane receptor, retinoid X receptor, and the vitamin D receptor, is warranted, and relevant investigations currently are in progress.

	Footnotes

 
ABBREVIATIONS: DHEA-S, dehydroepiandrosterone 3-sulfate; 16DHEA, 16-hydroxy DHEA; ECL, enhanced chemiluminescence; EGA, estimated gestational age; QRT-PCR, quantitative reverse transcriptase-polymerase chain reaction; Ct, cycle threshold; HPLC, high-performance liquid chromatography; bp, base pair(s); ANOVA, analysis of variance; RFLP, restriction fragment length polymorphism; DHEA16H, DHEA 16-hydroxylation; T2H, testosterone 2-hydroxylation; T6H, testosterone 6-hydroxylation.

This work was supported by Grant R01 ES10855-04 from the National Institute of Environmental Health Sciences.

doi:10.1124/jpet.105.086504.

Address correspondence to: Dr. J. Steven Leeder, Section of Developmental Pharmacology and Experimental Therapeutics, Children's Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108. E-mail: sleeder{at}cmh.edu

	References

Top Abstract Materials and Methods Results Discussion References

 

Barrett JC, Fry B, Maller J, and Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.[Abstract/Free Full Text]
Baulieu EE and Dray FL (1963) Conversion of ³H-dehydroepiandrosterone (3-hydroxy-5-androsten-17-one) sulfate to ³H-estrogens in normal pregnant women. J Clin Endocrinol Metab 23: 1298–1301.
Brudno M, Do C, Cooper G, Kim MF, Davydov E, Green ED, Sidow A, and Batzoglou S (2003) LAGAN and multi-LAGAN: efficient tools for large-scale multiple alignment of genomic DNA. Genome Res 13: 721–731.[Abstract/Free Full Text]
Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, Klein K, Fromm MF, Nuessler AK, Neuhaus P, et al. (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277: 24280–24288.[Abstract/Free Full Text]
Chen H, Fantel AG, and Juchau MR (2000) Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues. Drug Metab Dispos 28: 1051–1057.[Abstract/Free Full Text]
Hakkola J, Raunio H, Purkunen R, Saarikoski S, Vähäkangas K, Pelkonen O, Edwards RJ, Boobis AR, and Pasanen M (2001) Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 80: 193–201.[CrossRef][Medline]
Kitada M, Kamataki T, Itahashi K, Rikihisa T, and Kanakubo Y (1987) P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16-hydroxylase of dehydroepiandrosterone 3-sulfate. J Biol Chem 262: 13534–13537.[Abstract/Free Full Text]
Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler AC, Neuhaus P, Eichelbaum M, Zanger UM, and Wojnowski L (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30: 1108–1114.[Abstract/Free Full Text]
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly AK, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383–391.[CrossRef][Medline]
Lacroix D, Sonnier M, Moncion A, Cheron G, and Cresteil T (1997) Expression of CYP3A in the human liver. Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247: 625–634.[Medline]
Li Y, Yokoi T, Katsuki M, Wang JS, Groopman JD, and Kamataki T (1997) In vivo activation of aflatoxin B1 in C57BL/6N mice carrying a human fetus-specific CYP3A7 gene. Cancer Res 57: 641–645.[Abstract/Free Full Text]
Lu AYH and Levin W (1972) Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. Biochem Biophys Res Commun 46: 1334–1339.[CrossRef][Medline]
Marill J, Capron CC, Idres N, and Chabot GG (2002) Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem Pharmacol 63: 933–943.[CrossRef][Medline]
Marill J, Cresteil T, Lanotte M, and Chabot GG (2000) Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 58: 1341–1348.
Mesiano S and Jaffe RB (1997) Developmental and functional biology of the primate fetal adrenal cortex. Endocrine Rev 18: 378–403.[Abstract/Free Full Text]
Milewich L, MacDonald PC, Guerami A, Midgett WT, Lassiter WI, and Carr BR (1986) Human fetal liver estrogen 16-hydroxylase: precursor specificity, kinetic parameters and in vitro regulation. J Clin Endocrinol Metab 63: 180–191.[Abstract/Free Full Text]
Nakamura H, Torimoto N, Ishii I, Ariyoshi N, Nakasa H, Ohmori S, and Kitada M (2003) CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos 31: 432–438.[Abstract/Free Full Text]
Nebert DW (1991) Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation and neuroendocrine functions. Mol Endocrinol 5: 1203–1214.[Abstract/Free Full Text]
Nebert DW (1994) Drug-metabolizing enzymes in ligand-modulated transcription. Biochem Pharmacol 47: 25–37.[CrossRef][Medline]
Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, and Parkinson A (1996) Effects of freezing, thawing and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331: 145–169.[CrossRef][Medline]
Purdon MP and Lehman-McKeeman LD (1997) Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites. J Pharmacol Toxicol Methods 37: 67–73.[CrossRef][Medline]
Rodriguez-Antona C, Jande M, Rane A, and Ingelman-Sundberg M (2005) Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther 77: 259–270.[CrossRef][Medline]
Rogan PK, Svojanovsky S, and Leeder JS (2003) Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics 13: 207–218.[CrossRef][Medline]
Ryan KJ (1959) Metabolism of C-16 oxygenated steroids by human placenta. The formation of estriol. J Biol Chem 234: 2006–2008.[Free Full Text]
Schuetz JD, Kauma S, and Guzelian PS (1993) Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J Clin Investig 92: 1018–1024.
Serón-Ferré M and Jaffe RB (1981) The fetal adrenal gland. Annu Rev Physiol 43: 141–162.[CrossRef][Medline]
Siiteri PK and MacDonald PC (1963) The utilization of circulating dehydroepiandrosterone sulfate for estrogen synthesis during human pregnancy. Steroids 2: 713–730.[CrossRef]
Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, and Zaya MJ (2003) Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307: 573–582.[Abstract/Free Full Text]
Usmani KA, Rose RL, and Hodgson E (2003) Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals. Drug Metab Dispos 31: 384–391.[Abstract/Free Full Text]
van Schaik RHN, van der Heiden IP, van den Anker JN, and Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48: 1668–1671.[Abstract/Free Full Text]
Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5 and CYP3A7. Drug Metab Dispos 30: 883–891.[Abstract/Free Full Text]
Yang H-YL, Lee QP, Rettie AR, and Juchau MR (1994) Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol Pharmacol 46: 922–928.[Abstract]

This article has been cited by other articles:

				A. K. Riffel, E. Schuenemann, and C. A. Vyhlidal Regulation of the CYP3A4 and CYP3A7 Promoters by Members of the Nuclear Factor I Transcription Factor Family Mol. Pharmacol., November 1, 2009; 76(5): 1104 - 1114. [Abstract] [Full Text] [PDF]

				Y. Li, Y. Cui, S. N. Hart, C. D. Klaassen, and X.-b. Zhong Dynamic Patterns of Histone Methylation Are Associated with Ontogenic Expression of the Cyp3a Genes during Mouse Liver Maturation Mol. Pharmacol., May 1, 2009; 75(5): 1171 - 1179. [Abstract] [Full Text] [PDF]

				S. N. Hart, Y. Cui, C. D. Klaassen, and X.-b. Zhong Three Patterns of Cytochrome P450 Gene Expression during Liver Maturation in Mice Drug Metab. Dispos., January 1, 2009; 37(1): 116 - 121. [Abstract] [Full Text] [PDF]

				A. Gaedigk, D. W. Baker, R. A. Totah, R. Gaedigk, R. E. Pearce, C. A. Vyhlidal, D. C. Zeldin, and J. S. Leeder Variability of CYP2J2 Expression in Human Fetal Tissues J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 523 - 532. [Abstract] [Full Text] [PDF]

				R. E. Pearce, J. S. Leeder, and G. L. Kearns BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION Drug Metab. Dispos., June 1, 2006; 34(6): 1035 - 1040. [Abstract] [Full Text] [PDF]

				C. A. Vyhlidal, R. Gaedigk, and J. S. Leeder NUCLEAR RECEPTOR EXPRESSION IN FETAL AND PEDIATRIC LIVER: CORRELATION WITH CYP3A EXPRESSION Drug Metab. Dispos., January 1, 2006; 34(1): 131 - 137. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.105.086504v1 314/2/626    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leeder, J. S. Articles by Pearce, R. E. Search for Related Content PubMed PubMed Citation Articles by Leeder, J. S. Articles by Pearce, R. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB TESTOSTERONE